Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)
Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study
This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).
Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.
In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.
The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.
The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.
Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.
The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.
The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.
The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Tanun Jitwatcharakomol, MD
- Telefonní číslo: +66 90 962 3000
- E-mail: tanun.jit@mahidol.ac.th
Studijní záloha kontaktů
- Jméno: Natawat Sukumtanakul, MD
- Telefonní číslo: +66 90 985 6598
- E-mail: d.natawats@gmail.com
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
- Status post breast-conserving surgery
- Planned adjuvant breast-only radiotherapy
- No indication for regional nodal irradiation
- Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
- Age ≥18 years
Exclusion Criteria:
- Planned treatment using Deep Inspiration Breath Hold (DIBH)
- Bilateral breast cancer
- Previous radiotherapy to the ipsilateral breast
- Unable to tolerate either the prone or supine position
- Breast volume >750 cm³
- Pre-existing heart disease or lung disease
- Active connective tissue disease
- Pregnant or found to be pregnant
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Supine and Prone Whole-Breast Radiotherapy Planning
All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability. |
Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean Heart Dose in Supine Versus Prone Treatment Plans
Časové okno: within 4 weeks after both CT simulations
|
Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
|
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Časové okno: within 4 weeks after both CT simulations
|
Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Časové okno: within 4 weeks after both CT simulations
|
PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%). |
within 4 weeks after both CT simulations
|
|
Treatment time from initial setup to treatment completion
Časové okno: within 4 weeks after treatment completion
|
Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes. |
within 4 weeks after treatment completion
|
|
translational X Positioning Accuracy
Časové okno: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Y Positioning Accuracy
Časové okno: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Z Positioning Accuracy
Časové okno: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
Patient Satisfaction Score
Časové okno: within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position. |
within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
|
Radiation Therapist Satisfaction
Časové okno: within 1 hours after treatment completion
|
Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique. |
within 1 hours after treatment completion
|
|
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Časové okno: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity. |
Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Tanun Jitwatcharakomol, MD, Mahidol University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Karcinom Prsu In Situ
- Novotvary podle místa
- Novotvary
- Novotvary podle histologického typu
- Novotvary, žlázové a epiteliální
- Adenokarcinom
- Kožní choroby
- Nemoci prsu
- Karcinom
- Novotvary, duktální, lobulární a medulární
- Karcinom in situ
- Chování
- Onemocnění kůže a pojivové tkáně
- Společenské chování
- Novotvary prsu
- Karcinom, intraduktální, neinfiltrující
- Klamání
Další identifikační čísla studie
Další identifikační čísla studie
- 683/2569(IRB1)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .